
    
      CD19 has been extensively evaluated as a therapeutic target for relapsed or refractory B cell
      malignancy by chimeric antigen receptor T cell therapy,this is a single arm, open-label,
      single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients
      with refractory acute lymphoblastic leukemia and Lymphomas.
    
  